Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

86 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Characteristics and Outcomes of Patients With Relapsed/Refractory Multiple Myeloma After Exposure to Lenalidomide in First Line of Therapy: A Single Center Database Review in Greece.
Kastritis E, Ntanasis-Stathopoulos I, Theodorakakou F, Migkou M, Roussou M, Malandrakis P, Kanellias N, Eleutherakis-Papaiakovou E, Fotiou D, Spiliopoulou V, Gavriatopoulou M, Patel S, Majer I, Boukis C, Fetani A, Dimopoulos MA, Terpos E. Kastritis E, et al. Among authors: kanellias n. Clin Lymphoma Myeloma Leuk. 2024 Mar 19:S2152-2650(24)00110-1. doi: 10.1016/j.clml.2024.03.003. Online ahead of print. Clin Lymphoma Myeloma Leuk. 2024. PMID: 38616479 Free article.
Thrombotic and bleeding complications in patients with AL amyloidosis.
Fotiou D, Theodorakakou F, Spiliopoulou S, Gavriatopoulou M, Migkou M, Kanellias N, Eleutherakis-Papaiakovou E, Malandrakis P, Dialoupi I, Roussou M, Ntanasis-Stathopoulos I, Terpos E, Dimopoulos MA, Kastritis E. Fotiou D, et al. Among authors: kanellias n. Br J Haematol. 2024 May;204(5):1816-1824. doi: 10.1111/bjh.19331. Epub 2024 Feb 6. Br J Haematol. 2024. PMID: 38321638
Efficacy and immune modulation associated with the addition of IMiDs to Daratumumab backbone in multiple myeloma patients refractory to both drug classes: resetting synergistic activity.
Kostopoulos IV, Fotiou D, Gavriatopoulou M, Rousakis P, Ntanasis-Stathopoulos I, Panteli C, Malandrakis P, Migkou M, Angelis N, Kanellias N, Eleutherakis-Papaiakovou E, Theodorakakou F, Krevvata M, Terpos E, Dimopoulos MA, Tsitsilonis O, Kastritis E. Kostopoulos IV, et al. Among authors: kanellias n. Blood Cancer J. 2024 Feb 6;14(1):26. doi: 10.1038/s41408-024-00988-x. Blood Cancer J. 2024. PMID: 38321005 Free PMC article. No abstract available.
Belantamab mafodotin, lenalidomide, and dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma: Analysis of belantamab mafodotin-associated ocular adverse events and their impact on daily functioning from the part 1 of a phase 1/2 study.
Gavriatopoulou M, Ntanasis-Stathopoulos I, Malandrakis P, Fotiou D, Migkou M, Theodorakakou F, Spiliopoulou V, Kanellias N, Eleutherakis-Papaiakovou E, Roussou M, Psarros G, Kastritis E, Dimopoulos MA, Terpos E. Gavriatopoulou M, et al. Among authors: kanellias n. Am J Hematol. 2024 Mar;99(3):502-504. doi: 10.1002/ajh.27219. Epub 2024 Jan 25. Am J Hematol. 2024. PMID: 38270219 Clinical Trial. No abstract available.
Management and Outcomes of Anti-CD38 Refractory Patients: The Impact of Retreatment and of Subsequent Therapies.
Kastritis E, Theodorakakou F, Ntanasis-Stathopoulos I, Spiliopoulou V, Solia E, Malandrakis P, Syrigou R, Kokkali N, Migkou M, Eleutherakis-Papaiakovou E, Fotiou D, Roussou M, Kanellias N, Gavriatopoulou M, Terpos E, Dimopoulos MA. Kastritis E, et al. Among authors: kanellias n. Hemasphere. 2023 Nov 3;7(11):e975. doi: 10.1097/HS9.0000000000000975. eCollection 2023 Nov. Hemasphere. 2023. PMID: 37936678 Free PMC article. No abstract available.
Impact of daratumumab on stem cell mobilization and collection, engraftment and early post-transplant complications among multiple myeloma patients undergoing autologous stem cell transplantation.
Eleutherakis Papaiakovou E, Terpos E, Kanellias N, Migkou M, Gavriatopoulou M, Ntanasis-Stathopoulos I, Fotiou D, Malandrakis P, Theodorakakou F, Spiliopoulou V, Kostopoulos IV, Tsitsiloni O, Tsirigotis P, Dimopoulos MA, Kastritis E. Eleutherakis Papaiakovou E, et al. Among authors: kanellias n. Leuk Lymphoma. 2023 Dec;64(13):2140-2147. doi: 10.1080/10428194.2023.2253479. Epub 2023 Sep 1. Leuk Lymphoma. 2023. PMID: 37655597
Outcomes of patients with light chain (AL) amyloidosis after failure of daratumumab-based therapy.
Theodorakakou F, Fotiou D, Spiliopoulou V, Roussou M, Malandrakis P, Ntanasis-Stathopoulos I, Migkou M, Eleutherakis-Papaiakovou E, Kanellias N, Papanikolaou A, Gavriatopoulou M, Terpos E, Dimopoulos MA, Kastritis E. Theodorakakou F, et al. Among authors: kanellias n. Br J Haematol. 2023 Nov;203(3):411-415. doi: 10.1111/bjh.19042. Epub 2023 Aug 14. Br J Haematol. 2023. PMID: 37580907
Prospective phase 2 trial of daratumumab with dexamethasone in patients with relapsed/refractory multiple myeloma and severe renal impairment or on dialysis: The DARE study.
Kastritis E, Terpos E, Symeonidis A, Labropoulou V, Delimpasi S, Mancuso K, Zamagni E, Katodritou E, Rivolti E, Kyrtsonis MC, Roussou M, Fotiou D, Theodorakakou F, Ntanasis-Stathopoulos I, Hatjiharissi E, Kanellias N, Migkou M, Cheliotis G, Manousou K, Gavriatopoulou M, Dimopoulos MA. Kastritis E, et al. Among authors: kanellias n. Am J Hematol. 2023 Sep;98(9):E226-E229. doi: 10.1002/ajh.27001. Epub 2023 Jun 21. Am J Hematol. 2023. PMID: 37340832 Clinical Trial. No abstract available.
Prevalence of MGCS Among Patients With Monoclonal Gammopathies.
Theodorakakou F, Fotiou D, Gavriatopoulou M, Ntanasis-Stathopoulos I, Spiliopoulou V, Malandrakis P, Migkou M, Eleutherakis-Papaiakovou E, Kanellias N, Terpos E, Dimopoulos MA, Kastritis E. Theodorakakou F, et al. Among authors: kanellias n. Hemasphere. 2023 May 31;7(6):e908. doi: 10.1097/HS9.0000000000000908. eCollection 2023 Jun. Hemasphere. 2023. PMID: 37275739 Free PMC article. No abstract available.
86 results